Objective:

To evaluate the safety and efficacy of ipsilateral high-frequency repetitive transcranial magnetic stimulation (IL-HFS) in patients with brain tumours following motor-eloquent tumour resection.

Approach:

Key Findings:

• All patients demonstrated significant improvements in MRC grade (p < 0.05).
• Strength gains were greater in lower-limb myotomes.
• AMPAC scores improved in both IL-HFS and CL-LFS groups.
• No seizures or heating effects occurred during the study.
• One IL-HFS patient required wound revision; another experienced a syncopal episode without seizure features.
• Transient paraesthesia was reported by one patient.

Interpretation:

IL-HFS rTMS appears to be safe in the early post-operative period following tumour resection, with no significant adverse events reported.

Limitations:

• Small sample size with only ten patients.
• Short follow-up period for assessing long-term safety and efficacy.

Conclusion:

Preliminary findings support further prospective trials evaluating IL-HFS, alone or combined with CL-LFS, to optimize motor recovery in patients with brain tumours.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.